NASDAQ:RGEN - Repligen Stock Price, Forecast & News

Repligen trades on the NASDAQ under the ticker symbol "RGEN."

Repligen Co. (NASDAQ:RGEN) announced its quarterly earnings data on Thursday, February, 20th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.18 by $0.02. The biotechnology company had revenue of $69.47 million for the quarter, compared to analysts' expectations of $68.37 million. Repligen had a net margin of 9.28% and a return on equity of 6.50%. The firm's quarterly revenue was up 33.8% compared to the same quarter last year. During the same period last year, the firm posted $0.21 earnings per share. View Repligen's Earnings History.

Repligen updated its FY20 earnings guidance on Thursday, February, 20th. The company provided earnings per share (EPS) guidance of $1.07-1.12 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.10. The company issued revenue guidance of $309-319 million, compared to the consensus revenue estimate of $314.77 million.

7 analysts have issued 12 month price targets for Repligen's shares. Their forecasts range from $100.00 to $110.00. On average, they anticipate Repligen's share price to reach $106.14 in the next year. This suggests a possible upside of 5.0% from the stock's current price. View Analyst Price Targets for Repligen.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Repligen.

News headlines about RGEN stock have trended somewhat positive on Friday, InfoTrie reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Repligen earned a news impact score of 1.0 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Repligen.

Repligen saw a drop in short interest in January. As of January 15th, there was short interest totalling 2,420,000 shares, a drop of 29.4% from the December 31st total of 3,430,000 shares. Based on an average trading volume of 393,500 shares, the short-interest ratio is presently 6.1 days. Approximately 5.1% of the company's shares are short sold. View Repligen's Current Options Chain.

Some companies that are related to Repligen include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include Alibaba Group (BABA), NVIDIA (NVDA), Netflix (NFLX), Veeva Systems (VEEV), Micron Technology (MU), Xilinx (XLNX), salesforce.com (CRM), Corcept Therapeutics (CORT), Okta (OKTA) and Twilio (TWLO).

Repligen's stock is owned by many different of retail and institutional investors. Top institutional investors include State Street Corp (2.99%), Conestoga Capital Advisors LLC (2.43%), Fred Alger Management LLC (2.37%), 12 West Capital Management LP (2.26%), Geode Capital Management LLC (1.33%) and Lord Abbett & CO. LLC (1.23%). Company insiders that own Repligen stock include Anthony Hunt, Glenn L Md Cooper, Jon Snodgres, Karen A Dawes, Nicolas Barthelemy, Ralf Kuriyel, Roy T Eddleman and Thomas F Ryan Jr. View Institutional Ownership Trends for Repligen.

RGEN stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Point72 Asset Management L.P., Goldman Sachs Group Inc., Fred Alger Management LLC, Prudential Financial Inc., Loomis Sayles & Co. L P, Citigroup Inc. and AQR Capital Management LLC. Company insiders that have sold Repligen company stock in the last year include Anthony Hunt, Glenn L Md Cooper, Jon Snodgres, Karen A Dawes and Ralf Kuriyel. View Insider Buying and Selling for Repligen.

RGEN stock was bought by a variety of institutional investors in the last quarter, including 12 West Capital Management LP, Franklin Resources Inc., Bank of America Corp DE, California Public Employees Retirement System, XML Financial LLC, Panagora Asset Management Inc., Man Group plc and Barclays PLC. View Insider Buying and Selling for Repligen.

Shares of RGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of RGEN stock can currently be purchased for approximately $101.12.

Repligen has a market capitalization of $5.26 billion and generates $194.03 million in revenue each year. The biotechnology company earns $16.62 million in net income (profit) each year or $0.73 on an earnings per share basis. Repligen employs 548 workers across the globe.View Additional Information About Repligen.

The official website for Repligen is http://www.repligen.com/.

Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The biotechnology company can be reached via phone at 781-250-0111 or via email at [email protected]